revumenib
FDA Approves Revuforj for Relapsed or Refractory Acute Leukemia With a KMT2A Translocation
The FDA approved Revuforj, a menin inhibitor, for relapsed or refractory acute leukemia with a lysine ...
NOVEMBER 18, 2024
In Highly Pretreated KMT2A-Rearranged Leukemia, Novel Targeted Therapy Achieves MRD Negativity
In highly pretreated histone lysine N-methyltransferase 2A (KMT2A)-rearranged acute leukemia, a small molecule ...
FEBRUARY 9, 2024
Load more